Stories
India Food Regulator Targets Dr Reddy and Nestle Joint Venture Over GLP-1 Supplement Claims
C
CNBC TV18•09-10-2026, 07:52
India Food Regulator Targets Dr Reddy and Nestle Joint Venture Over GLP-1 Supplement Claims
- •The Food Safety and Standards Authority of India issued a notice to the joint venture between Dr Reddy Laboratories and Nestle India over misleading claims regarding their GLP-1 supplement.
- •Regulators flagged the brand name Celevida GLP+ and statements about lean muscle preservation and European import purity as ambiguous and misleading for consumers.
- •Notices were also issued to online sellers including Flipkart India and Amazon Seller Services for their role in distributing the product.
- •The joint venture had launched the high-protein powder in May to support individuals taking weight-loss and diabetes GLP-1 drugs.
- •This action is part of a broader crackdown by the FSSAI against companies making false claims in India, which has previously targeted firms like Dabur India.
Key Questions Answered
The Food Safety and Standards Authority of India issued notices to the joint venture between Dr. Reddy’s Laboratories Ltd. and Nestle India Ltd., as well as sellers including Flipkart India Pvt. and Amazon Seller Services Pvt.
The high-protein powder supplement was launched in May by Dr. Reddy’s and Nestle Health Science Ltd. to support nutrition and muscle mass maintenance for people taking weight-loss and diabetes GLP-1 drugs.
The regulator flagged brand claims such as high protein support for lean muscle preservation during GLP-1/GIP therapies and being imported from Europe for purity as misleading and ambiguous.
